文献速递心脑血管急症

氯吡格雷对比替格瑞洛或普拉格雷治疗70岁及以上非ST段抬高型急性冠脉综合征患者(POPular AGE):随机、开放标签、非劣效性试验

Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
PubMed 文献 · Lancet · 2020-01-01
一句话结论在70岁及以上NSTE-ACS患者中,氯吡格雷较替格瑞洛减少出血事件,且主要不良临床净效益终点非劣效。

POPular AGE试验在荷兰12个中心纳入1002例70岁及以上NSTE-ACS患者,随机接受氯吡格雷或替格瑞洛/普拉格雷(95%实际使用替格瑞洛)治疗12个月。氯吡格雷组主要出血终点(PLATO主要或次要出血)显著低于替格瑞洛组(18% vs 24%,HR 0.71,95%CI 0.54-0.94,优效性P=0.02)。共主要临床净效益终点(全因死亡、心肌梗死、卒中、PLATO主要及次要出血)氯吡格雷组28% vs 替格瑞洛组32%,绝对风险差-4%(95%CI -10.0至1.4),非劣效性P=0.03。作者认为氯吡格雷是老年NSTE-ACS患者的一种有利替代选择,尤其适用于出血风险较高的老年患者。

要点

  • 70岁及以上NSTE-ACS患者中,氯吡格雷组PLATO主要或次要出血发生率18%(88/500)显著低于替格瑞洛组24%(118/502),HR 0.71(95%CI 0.54-0.94),优效性P=0.02。
  • 共主要临床净效益终点(全因死亡、心肌梗死、卒中、PLATO主要及次要出血)氯吡格雷组28%(139/500)vs 替格瑞洛组32%(161/502),绝对风险差-4%(95%CI -10.0至1.4),非劣效性P=0.03。
  • 替格瑞洛组提前停药率47%(238/502),氯吡格雷组22%(112/500);停药最常见原因为出血(n=38)、呼吸困难(n=40)和需口服抗凝治疗(n=35)。
  • 作者认为,在70岁及以上NSTE-ACS患者中,氯吡格雷是替格瑞洛的一种有利替代选择,尤其适用于出血风险较高的老年患者。

适用人群与场景

  • 年龄70岁及以上、诊断为非ST段抬高型急性冠脉综合征(NSTE-ACS)的患者。

处置流程与药物剂量

  • 氯吡格雷组:负荷剂量300 mg或600 mg,随后维持剂量75 mg每日一次,持续12个月,在标准治疗基础上给药。
  • 替格瑞洛/普拉格雷组:替格瑞洛负荷180 mg或普拉格雷负荷60 mg,随后替格瑞洛90 mg每日两次或普拉格雷10 mg每日一次,持续12个月,在标准治疗基础上给药。

研究设计与关键结果

  • 开放标签、随机对照非劣效性试验,在荷兰12个中心(10家医院和2家大学医院)纳入1002例70岁及以上NSTE-ACS患者,按1:1随机分为氯吡格雷组(n=500)和替格瑞洛或普拉格雷组(n=502;其中475例(95%)接受替格瑞洛,故称为替格瑞洛组)。
  • 主要出血终点(PLATO主要或次要出血,优效性假设):氯吡格雷组18%(88/500)vs 替格瑞洛组24%(118/502),HR 0.71(95%CI 0.54-0.94),优效性P=0.02。
  • 共主要临床净效益终点(全因死亡、心肌梗死、卒中、PLATO主要及次要出血,非劣效性假设,界值2%):氯吡格雷组28%(139/500)vs 替格瑞洛组32%(161/502),绝对风险差-4%(95%CI -10.0至1.4),非劣效性P=0.03。
  • 提前停用研究药物:替格瑞洛组47%(238/502)vs 氯吡格雷组22%(112/500);停药最常见原因为出血(n=38)、呼吸困难(n=40)和需口服抗凝治疗(n=35)。

证据类型、等级与局限

  • 证据类型:随机、开放标签、非劣效性试验(POPular AGE),随访12个月,意向性治疗分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在70岁及以上NSTE-ACS患者中,氯吡格雷是替格瑞洛的一种有利替代选择,因为其出血事件更少,且未增加全因死亡、心肌梗死、卒中和出血的复合终点。
  • 作者认为,氯吡格雷可作为P2Y12抑制剂的一种替代选择,尤其适用于出血风险较高的老年患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Current guidelines recommend potent platelet inhibition with ticagrelor or prasugrel in patients after an acute coronary syndrome. However, data about optimal platelet inhibition in older patients are scarce. We aimed to investigate the safety and efficacy of clopidogrel compared with ticagrelor or prasugrel in older patients with non-ST-elevation acute coronary syndrome (NSTE-ACS).

METHODS: We did the open-label, randomised controlled POPular AGE trial in 12 sites (ten hospitals and two university hospitals) in the Netherlands. Patients aged 70 years or older with NSTE-ACS were enrolled and randomly assigned in a 1:1 ratio using an internet-based randomisation procedure with block sizes of six to receive a loading dose of clopidogrel 300 mg or 600 mg, or ticagrelor 180 mg or prasugrel 60 mg, and then a maintenance dose for the duration of 12 months (clopidogrel 75 mg once daily, ticagrelor 90 mg twice daily, or prasugrel 10 mg once daily) on top of standard care. Patient and treating physicians were aware of the allocated treatment strategy, but the outcome assessors were masked to treatment allocation. Primary bleeding outcome consisted of PLATelet inhibition and patient Outcomes (PLATO; major or minor bleeding [superiority hypothesis]). Co-primary net clinical benefit outcome consisted of all-cause death, myocardial infarction, stroke, PLATO major and minor bleeding (non-inferiority hypothesis, margin of 2%). Follow-up duration was 12 months. Analyses were done on intention-to-treat basis. This trial is registered with the Netherlands Trial Register (NL3804), ClinicalTrials.gov (NCT02317198), and EudraCT (2013-001403-37).

FINDINGS: Between June 10, 2013, and Oct 17, 2018, 1002 patients were randomly assigned to clopidogrel (n=500) or ticagrelor or prasugrel (n=502). Because 475 (95%) patients received ticagrelor in the ticagrelor or prasugrel group, we will refer to this group as the ticagrelor group. Premature discontinuation of the study drug occurred in 238 (47%) of 502 ticagrelor group patients randomly assigned to ticagrelor, and in 112 (22%) of 500 patients randomly assigned to clopidogrel. Primary bleeding outcome was significantly lower in the clopidogrel group (88 [18%] of 500 patients) than in the ticagrelor group (118 [24%] of 502; hazard ratio 0·71, 95% CI 0·54 to 0·94; p=0·02 for superiority). Co-primary net clinical benefit outcome was non-inferior for the use of clopidogrel (139 [28%]) versus ticagrelor (161 [32%]; absolute risk difference -4%, 95% CI -10·0 to 1·4; p=0·03 for non-inferiority). The most important reasons for discontinuation were occurrence of bleeding (n=38), dyspnoea (n=40), and the need for treatment with oral anticoagulation (n=35).

INTERPRETATION: In patients aged 70 years or older presenting with NSTE-ACS, clopidogrel is a favourable alternative to ticagrelor, because it leads to fewer bleeding events without an increase in the combined endpoint of all-cause death, myocardial infarction, stroke, and bleeding. Clopidogrel could be an alternative P2Y12 inhibitor especially for elderly patients with a higher bleeding risk.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Gimbel M, Qaderdan K, Willemsen L, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet. 2020. PMID: 32334703. doi:10.1016/S0140-6736(20)30325-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。